Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02022501 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration
A Phase 1 study, sponsored by Santen.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT02022501 is a Phase 1 study that has completed, run by Santen. The registered enrollment target is 10 participants.
The verdict
NCT02022501, a Phase 1 study, has completed, sponsored by Santen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability, bioactivity and pharmacokinetics of three concentrations of DE-120 after a single intravitreal injection in subjects with late stage exudative age-related macular degeneration.
Interventions
- DRUG DE-120
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-01 |
| Est. Completion | 2016-04-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02022501
The ClinicalTrials.gov registry entry for NCT02022501 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Santen, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DE-120 is the first listed.
NCT02022501 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02022501 about?
NCT02022501 is a clinical study titled "A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration". The purpose of this study is to assess the safety, tolerability, bioactivity and pharmacokinetics of three concentrations of DE-120 after a single intravitreal injection in subjects with late stage exudative age-related macular degeneration.
What is the current status of trial NCT02022501?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2014-01. Estimated completion is 2016-04-21.
What interventions are being tested in trial NCT02022501?
The interventions under investigation include: DE-120 (DRUG).
Who is sponsoring clinical trial NCT02022501?
This trial is sponsored by Santen, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.